Arrowhead's ARO-MAPT cuts brain tau by 73% in early trial, a first for RNAi delivery to the brain
What happened? Arrowhead Pharmaceuticals reported interim results on 14 October 2026 from an ongoing Phase 1/2a study of ARO-MAPT, an experimental RNA interference (RNAi) treatment for Alzheimer's disease and other tauopathies — a group of neurodegenerative disorders linked to a build-up of a protein called tau in the brain. In healthy volunteers, a single under-the-skin (subcutaneous) injection reduced the level of total tau in cerebrospinal fluid by a median of 73% by day 105, with the largest individual drop reaching 85%.
Why it matters: This is the first clinical evidence that RNAi can be delivered across the blood-brain barrier — the protective wall that keeps most drugs out of the brain — and achieve meaningful gene silencing there. RNAi drugs work by instructing cells to destroy specific messenger RNA molecules, stopping a disease-causing gene (here, tau) from being made in the first place. The depth and durability of the reductions suggest the drug could be given as little as once every three months, a practical advantage for a chronic brain disease. Arrowhead described the result as clinical validation of its TRiM delivery platform for the central nervous system.
Where it goes next: The data come from the healthy-volunteer portion of the study, so they show safety and target engagement rather than patient benefit. The readout supports moving ARO-MAPT forward in people with tau-related disease, and Arrowhead said it will review the full interim dataset in an investor webinar on the day of the announcement.
Read more: Arrowhead Pharmaceuticals, 14 October 2026